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Summary
Peanut allergy is an IgE-mediated adverse reaction to a subset of proteins found in peanuts.
Immunotherapy aims to desensitize allergic patients through repeated and escalating exposures
for several months to years using extracts or flours. The complex mix of proteins and variability
between preparations complicates immunotherapy studies. Moreover, peanut immunotherapy is
associated with frequent negative side effects and patients are often at risk of allergic reactions
once immunotherapy is discontinued. Allergen-specific approaches using recombinant proteins
are an attractive alternative because they allow more precise dosing and the opportunity to
engineer proteins with improved safety profiles. We tested whether Ara h 1 and Ara h 2, two
major peanut allergens, could be produced using chloroplast of the unicellular eukaryotic alga,
Chlamydomonas reinhardtii. C. reinhardtii is novel host for producing allergens that is genetically
tractable, inexpensive and easy to grow, and is able to produce more complex proteins than
bacterial hosts. Compared to the native proteins, algal-produced Ara h 1 core domain and Ara h
2 have a reduced affinity for IgE from peanut-allergic patients. We further found that
immunotherapy using algal-produced Ara h 1 core domain confers protection from peanut-
induced anaphylaxis in a murine model of peanut allergy.
Introduction
There is an urgent need to develop therapeutic approaches for
treating food allergy, a disease for which there is no cure and the
current standard of care is avoidance. A small number of foods,
including milk, egg, wheat, shellfish, tree nut and peanut,
account for the majority of food allergies (Soares-Weiser et al.,
2014), but accidental exposure is nonetheless difficult to avoid,
especially for individuals with multiple allergies. Approximately
6–8% of children are affected, which is a significant increase in
prevalence from recent decades (Panel et al., 2010). Fortunately,
many food allergies are outgrown during childhood. Peanut
allergy, however, is usually a lifelong condition that affects 1–2%
of the population, has no diagnostic test to predict severity, and is
the most common cause of fatal or near-fatal anaphylaxis. Thus,
the standard of care is strict avoidance and ready access to
epinephrine.
Peanut allergy is an IgE-mediated adverse reaction to specific
proteins found in the legume Arachis hypogaea (Berin and
Sampson, 2013). Thus far, sixteen proteins in A. hypogaea have
been identified as allergens (Ara h 1–Ara h 17, Ara h4 was
renamed to Ara h3.02; www.allergen.org); Ara h 1 and Ara h 2
are the dominant and best-characterized peanut allergens to
date. Peanut-allergic patients exhibit a TH2-polarized response to
peanut and IgE that recognize one or more allergens (Flinterman
et al., 2008, 2010). Upon exposure to peanut, IgE on tissue
resident mast cells and circulating basophils cross-link their
cognate allergen causing rapid degranulation and release of
histamine and inflammatory molecules (MacGlashan, 2008). This
cascade leads to allergic reactions ranging from mild rash and
gastrointestinal distress to fatal systemic anaphylaxis and organ
failure.
Treatment of food allergies using allergen-specific
immunotherapy delivered by oral, sublingual or epicutaneous
routes is a promising treatment option for food allergy (Wang and
Sampson, 2012). Although the mechanism of protection remains
unclear, immunotherapy aims to increase the threshold of
allergen required to elicit an allergic response through repeated
and escalating doses of the offending allergen in extract, powder
or other form. The risk of adverse therapy-induced side effects,
including anaphylaxis, is high for peanut allergy. Crude peanut
extracts complicate therapeutic approaches because they contain
complex and variable mixtures of proteins. There may be
components of peanut extracts that contribute to sensitization
(Tordesillas et al., 2014). Immunotherapy using crude extracts
can also increase the risk of future adverse reactions by
introducing new IgE specificities to an allergic patient’s IgE
repertoire (Vickery et al., 2013) and, once patients discontinue
therapy, adverse reactions return. Thus, peanut immunotherapy is
not recommended in clinical practice (Sampson, 2013).
Recombinant proteins are an attractive alternative to native
allergens for immunotherapy and allergy diagnostics (Codreanu
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et al., 2011). Recombinant allergens can be purified without
concern for contamination by cross-reactive peanut proteins. This
facilitates accurate component testing of allergic patient IgE
repertoires and more defined doses of individual allergens for
immunotherapy. They also provide greater flexibility and speci-
ficity because the native polypeptide sequence serves only as a
starting point. For example, recombinant allergens can be
engineered to reduce IgE cross-linking on mast cells and basophils
that initiate allergic responses. Mutagenesis of critical amino acids
in IgE binding epitopes of Ara h 1, Ara h 2 and Ara h3 reduced
the binding to IgE from peanut-allergic patients (Li et al., 2003a).
Immunotherapy using rectally administered heat-killed Escher-
ichia coli that produce modified Ara h 1–3 mitigated peanut-
induced anaphylaxis in a murine peanut allergy model, possibly
due to the adjuvant effect of using E. coli as a delivery vehicle.
Similar results were observed after subcutaneous administration
of modified Ara h 1–3 in Listeria monocytogenes (Li et al.,
2003b). Indeed, protection from peanut allergy is associated with
a shift from TH2 to TH1 immune responses to peanut. Unfortu-
nately, phase I clinical trials demonstrated that allergens with
modified IgE binding sites could still trigger reactions in humans
when rectally administered using heat-killed E. coli (Wood et al.,
2013).
Recent advances in molecular biology and genetic engineering
have expanded the breadth of organisms that can be used to
produce recombinant proteins, some of which have characteris-
tics that may be beneficial for food allergy immunotherapy. For
example, Lactococcus lactis, a genetically tractable member of
the lactic acid producing bacteria, is safe for oral delivery and is
being studied for use as a probiotic. Ara h 2 produced and orally
delivered to mice using L. lactis cells, which can promote an
immunomodulatory effect to recombinant proteins (Neutra and
Kozlowski, 2006), resulted in reduced peanut-specific IgE pro-
duction and TH2 cytokines when used prophylactically (Ren et al.,
2014). Plants are also attractive platforms for producing allergens,
both because many allergens are of plant origin and because they
provide an inexpensive scalable system that is not prone to
infection by human pathogens (Schmidt et al., 2008). Nicotiana
benthamiana, a well-established tobacco system, has been used
to make allergens from birch pollen (Krebitz et al., 2000),
mugwort pollen (Siegert et al., 2012) and apple (Krebitz et al.,
2003). Hypoallergenic birch pollen allergens were recently made
in rice (Ogo et al., 2014). Oral delivery of transgenic rice seeds
containing T-cell epitopes from Cry j 1 and Cry j 2, the major
Japanese cedar pollen allergens, lowers vaccination-induced IgE
and T-cell responses (Takagi et al., 2005).
The purpose of this study was to assess the feasibility of
producing recombinant peanut allergens using the chloroplast of
the unicellular eukaryotic green alga, Chlamydomonas reinhardtii.
Relative to terrestrial plants, C. reinhardtii can be rapidly trans-
formed into stable transgenic strains and scaled to large volumes
using minimal growth media in fully contained photobioreactors.
Thus, algal-derived recombinant proteins could be produced
quickly and inexpensively. Costs will be further reduced by
advances in cultivation and harvesting lead by industrial algal
production for biofuel and commercial products. The tools to
express transgenes from the nuclear and chloroplast genomes,
both of which have been fully sequenced, are readily available.
Thus far, algae have been used to produce single chain antibodies
(Mayfield et al., 2003), full-length human antibodies (Tran et al.,
2009), vaccine antigens (Surzycki et al., 2009), human therapeu-
tic proteins (Rasala et al., 2010) and even multiprotein biosyn-
thetic pathways (Noor-Mohammadi et al., 2012). Here we
demonstrate that C. reinhardtii can produce Ara h 1 and Ara h
2, two structurally distinct peanut allergens, and these recombi-
nant allergens have reduced IgE binding compared to the native
proteins. We further demonstrate that immunotherapy using
algal-produced Ara h 1 reduces anaphylaxis in a murine model of
peanut allergy.
Results
Construction of transgenic chloroplasts in
Chlamydomonas reinhardtii
We reverse-translated the peptide sequences of Ara h 1 and Ara
h 2 from Arachis hypogaea using a C. reinhardtii chloroplast
codon bias (see materials and methods). Codon optimization has
been shown to increase transgene expression in algal chloro-
plasts (Franklin et al., 2002). Codon-optimized Ara h 1 and Ara
h 2, hereafter referred to as CrAra h 1 and CrAra h 2,
respectively, and a truncated CrAra h 1 consisting of amino
acids 171–586 (CrAra h 1171-586) encoding the core domain of
Ara h 1 (Figure 1a) were separately cloned into chloroplast
expression vector pJAG15 (Figure 1b (Gregory et al., 2012)) and
confirmed by Sanger sequencing. This expression cassette adds
a carboxy terminal TEV protease site followed by a FLAG-tag
and confers kanamycin resistance. Stable transgene integration
into the chloroplast genome at the psbA locus is achieved via
homologous recombination. Thus, transcription is controlled by
the light dependent psbA promoter and 50 and 30 untranslated
regions (UTRs; Figure 1b). Successful integration of CrAra h 1
(JAG231), CrAra h 1171–586 (JAG234) and CrAra h 2 (JAG194)
into the plastid genome using particle bombardment was
confirmed by PCR (Figure 1c). Four isolates of each transgenic
algal strain were screened for recombinant protein accumulation
by Western blot using anti-FLAG antibodies (Figure 1d–e).
C. reinhardtii that produce CrAra h 1171–586 and CrAra h 2
were successfully isolated, but we were unable to detect CrAra
h 1 protein accumulation in any of the screened isolates (data
not shown). Previous structural studies of recombinant Ara h 1
from Escherichia coli suggest that full-length recombinant Ara h
1 is less stable than the core domain (Chruszcz et al., 2011).
Thus, full-length CrAra h 1 may also be unstable in algal
chloroplasts. The apparent molecular weight of monomeric
CrAra h 1 h1171–586 as observed by SDS-PAGE is slightly larger
than the predicted 50 kDa (Figure 1d, arrow). The major CrAra
h 2 band migrates near the predicted 22 kDa (Figure 1e, arrow).
A minor fraction of CrAra h 1 and CrAra h 2 appear to
assemble into dimers and higher molecular weight complexes,
respectively. No bands were observed in the untransformed
parental C. reinhardtii strain, indicating successful production of
these peanut allergens.
Characterization of algal-produced peanut allergens
CrAra h 1 h1171–586 and CrAra h 2
Affinity-purified CrAra 1 h1171–586 (hereafter referred to as CrAra
h 1-core) and CrAra h 2 were analysed by Western blot using Ara
h 1 or Ara h 2 specific antibodies, respectively, and compared to
the native proteins. Ara h 1 and Ara h 2 were purified from
peanuts as previously described (Hurlburt et al., 2014). Ara h 1
specific antibodies recognize both Ara h 1 and CrAra h 1-core
(Figure 2a); Ara h 1 migrates near the predicted 70 kDa and
CrAra h 1-core migrates slightly larger than the predicted 50 kDa
(Figure 2a, arrow). Purified CrAra h 1-core resolved by SDS-PAGE
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and stained with Coomasie blue revealed a single major species
(Figure 2b, arrow) and minor larger molecular weight species.
Similarly, antibodies specific for Ara h 2 recognize both Ara h 2
and CrAra h 2. The 16-kDa and 22-kDa isoforms of Ara h 2 were
detected by Western blot (Figure 2c). CrAra h 2 also appears as a
doublet; the larger species migrates near the predicted 22 kDa
for CrAra h 2 (Figure 2c, arrow), but the smaller CrAra h 2 species
is likely a degradation product of full-length CrAra h 2. Larger
molecular weight species of CrAra h 2 observed in Western blots
of algal lysates were less prevalent. SDS-PAGE separation
followed by Coomassie blue staining of affinity-purified CrAra h
2 revealed the 22-kDa CrAra h 2 as the major species (Figure 1d,
arrow); however, multiple minor species were also observed.
CrAra h 1-core and CrAra h 2 were evaluated for the presence
of human IgE binding epitopes using serum from eight peanut-
allergic patients (hereafter referred to as allergic) obtained from
the Food Allergy Resource Initiative repository (Table S1). Ara h 1-
and Ara h 2-specific IgE from patient samples had at least twofold
higher OD than nonallergic controls as measured by ELISA (data
not shown). IgE binding to native and algal-produced allergens
was observed in serum from allergic patients, but not controls
(Figure 2e–f); IgE binding to CrAra h 1-core and CrAra h 2 was
significantly reduced compared to the native proteins. However,
differences in sample purity could account for the disparate IgE
binding. We therefore tested the relative affinity of IgE for na€ıve
versus algal-produced Ara h 1 and Ara h 2 more directly using a
competition ELISA. Briefly, pooled serum was pre-incubated with
native or recombinant allergens at increasing concentrations and
subsequently added to an ELISA plate precoated with Ara h 1 or
Ara h 2. Increasing the concentration of Ara h 1 or Ara h 2 in pre-
incubated serum decreased IgE binding to plate-bound allergen
by approximately 60% at the highest concentrations tested
(Figure 2g–h). CrAra h 1-core and CrAra h 2 decreased binding to
plate-bound Ara h 1 or Ara h 2, respectively, by <20% at
equivalent concentrations. These results suggest that IgE from
allergic patients preferentially bind to native allergens over algal-
produced allergens.
Immunotherapy using algal-produced Ara h 1
We employed a mouse model of peanut allergy to test whether
CrAra h 1-core could be used for desensitization to native Ara h
1. Similar to humans, peanut sensitized mice have increased
peanut-specific IgE, basophils that are activated by peanut
allergens, and suffer anaphylaxis upon peanut exposure. Recent
studies suggest that exposure to peanut through the skin may
contribute to the initial sensitization. We therefore utilized a
model of peanut allergy whereby mice are sensitized through
weekly skin exposure (Tordesillas et al., 2014). This model does
not require the use of adjuvants or tape stripping to induce skin
damage and inflammation. Following sensitization, mice were
treated with increasing doses of Ara h 1 or CrAra h 1-core or left
untreated for 4 weeks (Figure 3a; see Materials and methods).
Prior to allergen challenge, blood was pooled from each group
and tested for Ara h 1-specific IgE and IgG1 and allergen-specific
basophil activation. In pooled samples, we observed slightly
higher serum IgE levels in CrAra h 1-core-treated mice compared
to Ara h 1-treated mice, and both of these groups had elevated
serum IgE compared to sensitized but untreated controls
(Figure 3b). Ara h 1-specific IgE was not detected in na€ıve mice.
IgG1 levels were elevated in both native and CrAra h 1-core-
treated groups compared to untreated controls (Figure 3c).
Basophil activation was measured by flow cytometry as the
median fluorescence intensity (MFI) of CD200R expression
(Figure 3d). Briefly, we gated out B and T cells (CD19 and CD3,
respectively) and selected IgE and CD49b positive cells. CD200R is
expressed on murine basophils and is up-regulated upon cross-
(a)
(b)
(d)(c)
(e)
Figure 1 Construction and validation of transplastomic Chlamydomonas reinhardtii strains expressing CrAra h 1 or CrAra h 2. (a) Diagram of recombinant
Ara h 1, the core domain of Ara h 1, Ara h 2 and the (b) chloroplast transformation vector used to insert peanut allergen genes into the psbA locus of the
C. reinhardtii plastid genome. Grey flag—TEV protease site. Red flag—FLAG affinity epitope. (c) Parental, transplastomic algal strains, and assembled
chloroplast vectors were screened by PCR for the presence of CrAra h 1, CrAra h 1171–586 or CrAra h 2. (d) Western blot analysis of soluble protein extracts
from parental and four isolates of transformed algae for CrAra h 1171–586 or CrAra h 2 with anti-FLAG antibodies. JAG231—CrAra h 1. JAG234—CrAra h
1171–586. JAG194—CrAra h 2.
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linking to allergen and subsequent activation. We observed
increased Ara h 1-dependent activation in basophils from
sensitized compared to na€ıve mice, and activation was moder-
ately reduced in Ara h 1- and CrAra h 1-core-treated mice,
despite elevations in allergen-specific IgE. We also observed a
reduction in activation by Ara h 2 in basophils from Ara h 1- and
CrAra h 1-core-treated mice, suggesting CrAra h 1-core induces
bystander suppression.
Systemic challenge using Ara h 1, Ara h 2 or peanut extract
induces anaphylaxis in mice that are sensitized to peanut through
the skin, which can be measured by a drop in core body
temperature. We performed a dose escalation challenge using
purified Ara h 1 one week post-immunotherapy to test whether
Ara h 1 or CrAra h 1-core immunotherapy could protect peanut
sensitized mice from anaphylaxis. Rectal temperatures were
recorded at baseline and 30 min after each challenge (Figure 3e).
Decreases in body temperature indicative of anaphylaxis were
observed at the 50- and 88-lg dose (highest dose possible due to
the concentration of purified Ara h 1 used). Surprisingly, CrAra h
1-core-treated mice, but not Ara h 1-treated mice, were
significantly protected from anaphylaxis after a 50-lg challenge.
Statistical significance was lost at the highest dose for all but the
na€ıve mice. Thus, CrAra h 1-core immunotherapy protects peanut
sensitized mice from Ara h 1-induced anaphylaxis.
We sought to determine whether immunotherapy using CrAra
h 1-core also provided protection against exposure to peanut
extract. Mice were sensitized as before, and after 4 weeks of
CrAra h 1-core immunotherapy (Figure 4a), basophils from each
mouse were tested individually (rather than in pooled groups as in
Figure 3) for reactivity to peanut extract. We did not observe a
reduction in peanut extract dependent basophil activation (Fig-
ure 4b). IgE and IgG1 levels were similar to those in Figure 3 (data
not shown). Immunotherapy was continued for an additional
week and each mouse was retested for basophil reactivity to Ara
h 1. Similar to pooled groups tested previously (Figure 3c),
activation appeared to be reduced in CrAra h 1-core-treated mice
at both concentrations of Ara h 1 tested (Figure 4c). However,
the reduction in basophil activation did not reach statistical
significance. We next performed a dose escalation challenge
using peanut extract and recorded rectal temperatures at baseline
and 30 min after each challenge. Untreated mice showed a
decrease in body temperature after the 10-lg dose, which
continued to drop after the 50-lg dose, indicative of severe
anaphylaxis (Figure 4d). In contrast, CrAra h 1-core-treated mice
(a) (b) (e)
(f)
(g)
(h)(c) (d)
Figure 2 Immunoblot, Coomassie blue staining and IgE binding of purified CrAra h 1171–586 and CrAra h 2. FLAG affinity-purified CrAra h 1171–586 (a–b) or
CrAra h 2 (c–d) was separated by SDS-PAGE, transferred to nitrocellulose and detected by Western blot using allergen-specific antibodies or Coomassie
blue staining. IgE that recognizes (e) Ara h 1 or CrAra h 1171–586, or (f) Ara h 2 or CrAra h 2 from serum in healthy controls or peanut-allergic patients was
detected by ELISA. Statistical significant was calculated using a paired t-test. (g–h) Competition ELISA—equal volumes of serum from peanut-allergic
patients were pooled and pre-incubated with increasing concentrations of (g) Ara h 1 or CrAra h 1171–586, or (h) Ara h 2 or CrAra h 2 and added to ELISA
plates precoated with the corresponding native allergen. Each sample was tested in triplicate. *p = .05.
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were protected at the 10-lg dose and only a slight drop in
temperature was observed after the 50-lg dose. Mouse mast cell
protease 7 (mMCP-7) levels were measured in blood serum
immediately following challenge as an additional marker of
anaphylaxis. We observed a significant reduction in CrAra h 1-
core-treated mice compared to untreated controls (Figure 4e).
Thus, immunotherapy using CrAra h 1-core provides bystander
suppression to additional peanut allergens.
Discussion
In this study, we demonstrate that algal chloroplasts can produce
two of the major peanut allergens: the core domain of Ara h 1
and full-length Ara h 2. Compared to the native allergens, these
recombinant algal-produced allergens have reduced binding to
IgE from peanut-allergic patients. We tested the efficacy of
immunotherapy using the algal-produced Ara h 1 core domain in
an adjuvant-free murine model of peanut allergy that sensitizes
mice through the skin, a route that mimics sensitization in some
humans. In this model, we found that algal-produced Ara h 1
core, but not native Ara h 1, significantly protects peanut
sensitized mice from anaphylaxis induced by purified Ara h 1 or
peanut extract, which demonstrates that systemic treatment with
algal-produced Ara h 1 confers antigen specific and bystander
suppression to peanut allergens.
Food allergens from different sources (e.g. peanut, egg and
recombinant) have various physical and enzymatic properties that
contribute to IgE binding and allergenicity, including glycosyla-
tion, binding to pattern recognition receptors, or protease
activity. The inability of algal-produced peanut allergens to
outcompete native allergens for IgE binding suggests key
differences in structure. CrAra h 1-core contains 9 of the 12
known linear Ara h 1 IgE binding epitopes (Burks et al., 1997) and
CrAra h 2 contains all of the known linear Ara h 2 IgE binding
epitopes (Stanley et al., 1997). These linear epitopes are identical
to those found on the native proteins. Thus, algal-produced
allergens may have fewer or malformed conformational IgE
epitopes. Studies of predominant IgE binding epitopes on Ara h 1
and Ara h 2 have focused primarily on linear epitopes using short
synthetic peptides (Flinterman et al., 2008; Lin et al., 2012).
However, analysis of IgE binding epitopes from humans and rats
using phage display libraries identified dominant epitopes that are
conformational and not linear (Bogh et al., 2012, 2014).
Different post-translational modifications could also lead to
reduced IgE binding. The observed molecular weight of CrAra h
1-core domain (55 kDa) is slightly larger than the predicted one
(50 kDa), possibly indicating post-translational modifications,
although a discrepancy between actual and observed molecular
weight using SDS-PAGE is not uncommon. Native Ara h 1 is
glycosylated at two amino acid residues and undergoes sponta-
neous modifications through a Maillard reaction leading to
advanced glycation end products (AGEs), especially when roasted
(Hebling et al., 2013). C. reinhardtii chloroplasts lack the machin-
ery for glycosylation and AGE modifications are not present on
(a) (b) (c)
(d) (e)
Figure 3 Impact of Ara h 1 or CrAra h 1171–586 immunotherapy on Ara h 1-specific IgE, basophil activation and anaphylaxis in peanut sensitized mice. (a)
Sensitization, immunotherapy, and Ara h 1 basophil activation and challenge schedule. Mice were sensitized to peanut using weekly exposures to peanut
extract through the skin for 6 weeks followed by 4 weeks of immunotherapy—1 lg (weeks 1 and 2), 2 lg (week 3), 5 lg (week 4) of Ara h 1 or the molar
equivalent of CrAra h 1 h1171–586. Blood was pooled from each group prior to challenge and tested for (b) Ara h 1-specific serum IgE and (c) IgG1 by
ELISA and (d) basophil activation by Ara h 1, Ara h 2 or peanut extract (CPE) as measured by an increase in CD200R by flow cytometry. Purified Ara h 1 was
used in a dose escalation challenge (e). Anaphylaxis was measured as a drop in body temperature compared to baseline 30 min after each challenge
1 week after completing immunotherapy. Results are displayed as individual data points and average  SEM are shown. Statistical significance was
calculated using one-way ANOVA followed by Bonferroni correction for multiple comparisons. *p < .05, **p < .01.
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recombinant Ara h 1 from E. coli (Mueller et al., 2013), which
also has reduced IgE binding compared to native Ara h 1
(Chruszcz et al., 2011). The absence of glycosylation and AGEs
on CrAra h 1 could therefore lead to decreased IgE affinity.
Acetylation has been reported for proteins produced or shuttled
to the chloroplast (Lehtimaki et al., 2015). Interestingly, acetyla-
tion of Art v 1, the major mugwort pollen allergen, reduces
allergenicity in vivo and in vitro (Perovic et al., 2009). Further
structural characterization will be necessary to elucidate the
relationship of reduced IgE binding and the structure of algal-
produced peanut allergens to determine whether this phe-
nomenon is specific to Ara h 1 and Ara h 2 or a more general
characteristic of chloroplast-produced proteins.
Allergen-specific immunotherapy can reduce clinical symptoms
through suppression of effector mast cells and basophils
(Matsuoka et al., 2013). Algal Ara h 1 core domain may mitigate
peanut-induced anaphylaxis through elevated Ara h 1-specific
IgG1 and reduced mast cell activation. Indeed, peanut-induced
anaphylaxis from IP challenge is primarily mast cell and IgE-
dependent (Sun et al., 2007). Allergen-specific IgE levels were in
fact elevated in treated mice compared to untreated mice, a
paradox which has also been observed after allergen
immunotherapy in allergic patients (Vickery et al., 2014). IgG
antibodies have been proposed to play a protective role in food
allergy (Burton et al., 2014) and correlate with clinical protection
following immunotherapy (Vickery et al., 2013). Allergen-specific
IgG can act directly through sequestration of allergen (Kucuk
et al., 2012) or by reducing activation of mast cells, which are key
mediators of allergic responses (Voehringer, 2013) in peanut
allergy (Reber et al., 2013). Allergen-specific IgG promote inter-
nalization of IgE-FceRI complexes (Uermosi et al., 2014) and
reduce downstream signalling through the low-affinity Fcc
receptor IIB (Uermosi et al., 2010). Both Ara h 1- and CrAra h
1-core-treated mice had elevated levels of IgG1 compared to
(a)
(b) (c)
(d) (e)
Figure 4 Impact of CrAra h 1 171–586 immunotherapy on basophil activation and anaphylaxis by peanut extract in peanut sensitized mice. (a) Sensitization,
immunotherapy, basophil activation and challenge schedule. Sensitization and immunotherapy were performed as before except in week 5, two additional
doses were given following the first basophil activation. (b–c) Blood was drawn from each mouse and tested individually for basophil activation by Ara h 1
(BAT 1) or CPE (BAT 2) as measured by an increase in CD200R expression using flow cytometry. (d) Peanut extract was used in a dose escalation challenge
1 week after completing immunotherapy. Anaphylaxis was measured as a drop in body temperature compared to baseline 30 min after each challenge. (e)
Blood was drawn immediately after the final challenge and mMCP-7 levels were measured in serum by ELISA. Statistical significance for challenge data was
calculated using a one-way ANOVA followed by Bonferroni multiple-comparison correction. mMCP-7 levels were compared using a Mann–Whitney test.
*p < .05, **p < .01, ****p < .0001.
ª 2016 The Authors. Plant Biotechnology Journal published by Society for Experimental Biology and The Association of Applied Biologists and John Wiley & Sons Ltd., 14, 1541–1550
James A. Gregory et al.1546
untreated controls. Thus, increases in Ara h 1-specific IgG is not
sufficient for protection in our model. Foxp3+ regulatory T cells
have been shown to be suppressive in other models of allergen
immunotherapy for food allergy (Mondoulet et al., 2015) and
future studies should investigate their role in the context of algal-
produced allergens.
Our studies demonstrate the utility of algae as a host for
producing allergens for peanut immunotherapy, but the limita-
tions in this study should be considered. Administration of
peanut allergens systemically for immunotherapy is not feasible
in humans due to risk of adverse reactions (Nelson et al., 1997).
However, the production of these allergens in algae allows for
oral or sublingual delivery without extensive purification of
allergens. Whole-cell oral delivery using algal cells has been
used to induce mucosal and systemic immune responses,
demonstrating the bioavailability of proteins delivered by this
approach (Dreesen et al., 2010; Gregory et al., 2013). Oral
delivery of recombinant human blood proteins using tobacco
induces tolerance through regulatory T cells (Wang et al.,
2015). Systemic allergen challenge is also not a physiologic
route of exposure, but we anticipate that interventions that can
successfully suppress reactions to systemic allergen would be
effective independent of route of exposure. An oral route of
allergen challenge may be useful in future to address mucosal-
specific protective mechanisms such as peanut-specific IgA that
may be induced in the context of oral or sublingual
immunotherapy.
Experimental procedures
Plasmid construction
Ara h 1 (accession: P43238) and Ara h 2 (accession: AAN77576)
peptide sequences were reverse-translated using Gene Designer
(DNA 2.0 Inc., Menlo Park, CA) and synthesized (GeneWiz, La
Jolla, CA). Codon optimization was accomplished using a
reference set for the chloroplast of C. reinhardtii and verified by
calculating the codon adaptation index (CAI (Puigbo et al., 2008);
CrAra h 1: 0.93, CrAra h 2: 0.951). CrAra h 1 and CrAra h 2 were
cloned into pJAG15 (Gregory et al., 2012) to yield pJAG231 and
pJAG194, respectively, after digestion with NdeI and AgeI. The
core domain of Ara h 1 (accession 3S7E_A) was amplified by PCR
and cloned into pJAG15 to yield pJAG234. Correct assembly of all
plasmids was verified by Sanger sequencing (GeneWiz). Descrip-
tions of the completed chloroplast integration vectors can be
found in Figure 1.
Chlamydomonas reinhardtii growth and transformation
All strains were grown in Tris Acetate Phosphate (TAP) media at
room temperature on a rotary shaker with or without light as
indicated. C. reinhardtii strain DpsbA (Gregory et al., 2013) was
used for all transformations, which were carried out by particle
bombardment (Boynton et al., 1988). Briefly, 550-nm or 1000-
nm gold particles were coated with the appropriate plasmid DNA
as recommended by the manufacturer (Seashell Technologies,
San Diego, CA) and shot into 5 9 107 cells plated on TAP agar
plates supplemented with 100 lg/mL kanamycin using gene gun
(Bio-Rad, Hercules, CA). Plates were grown in the dark for 24–
48 h followed by constant illumination until colonies appeared
(6–10 days). Colonies were patched onto TAP agar plates
supplemented with 150 lg/mL kanamycin. Colonies that
continued to grow were screened using gene-specific primers
as previously described (Rasala et al., 2010).
Large-scale cultures were performed in 20-l photobioreactors.
Photobioreactors were constructed as previously described (Gre-
gory et al., 2012). Circulation was provided using forced air (Gast
Manufacturing, Benton Harbor, MI; Air pump model: DOA-P704-
AA) through a 0.2-lm filter. Cultures were grown to mid-log
phase and switched to constant illumination for 24–48 h before
harvesting. Cells were harvested using a peristaltic pump (Cole-
Parmer, Vernon Hills, IL; Masterflex model 73700-62) and the
volume was reduced to ~ 600 mL using a continuous-flow
centrifuge (WVO Designs, North Charleston, SC; model Extreme
Raw Power) at 6000 rpm. Cells were then pelleted by centrifu-
gation and snap frozen using liquid nitrogen and stored
at -80 °C.
Western blotting and affinity purification
Transformed C. reinhardtii strains were screened for CrAra h 1
and CrAra h 2 protein accumulation by Western blot. Briefly,
10 mL of TAP media supplemented with 50 lg/mL kanamycin in
test tubes was inoculated from plates and grown on a roller
drum (Fischer Scientific, model 1640) for 48–72 h in the dark
and switched to constant illumination for 24 h. Harvested cells
were resuspended in lysis buffer (50 mM Tris pH 8.0, 400 mM
NaCl, 0.5% Tween-20, protease inhibitor cocktail (Sigma, St.
Louis, MO) and lysed by sonication (Qsonica, Newtown, CT;
Microson ultrasonic cell disruptor). Lysates were cleared by
centrifugation, prepped with Novex LSD sample buffer (Life
Technologies, Carlsbad, CA) supplemented with 5% b-mercap-
toethanol, heated to 85 °C for 10 min and resolved using
NuPage Bis-Tris 4–12% precast gels (Life Technologies). Samples
were transferred to nitrocellulose, blocked with 5% milk in Tris-
buffered saline (50 mM Tris, 150 mM NaCl) with 0.1% Tween-20
(TBS-T) and probed with a mouse anti-Flag mAb (Sigma)
followed by alkaline phosphatase-conjugated anti-mouse IgG.
Blots were visualized using nitroblue tetrazolium (NBT) and 5-
bromo-4-chloro-3-indolyl phosphate (BCIP) in alkaline phos-
phatase buffer.
CrAra h 1 and Cr Ara h 2 were purified from 20-l photobiore-
actor cultures (described above) as follows. Frozen pellets were
resuspended in lysis buffer with protease inhibitors and lysed by
sonication (Branson Ultrasonics, Danbury, CT; model 450). M2
anti-Flag affinity resin (Sigma) washed with lysis buffer was added
to cleared lysates and rotated end over end at 4 °C for 2–4 h.
Resin was pelleted by centrifugation and washed three times with
20 column volumes with lysis buffer and once with lysis buffer
without Tween. Resin was collected by filtration in 5 mL
polypropylene columns and eluted with 100 mM glycine pH 3.5
with 400 mM NaCl. Eluted fractions were neutralized with 1 M
Tris pH 8.0 to a final concentration of 50 mM and tested for
protein by Western blot. Fractions were combined and buffer
exchanged to phosphate-buffered saline (PBS) pH 7.4 using
Vivaspin 6 columns (GE Healthcare Life Sciences, Pittsburgh, PA)
with a 10-kDa molecular weight cut-off. Protein concentration
was determined using the Bio-Rad Protein DC assay and analysed
by SDS-PAGE followed by Western blot with allergen-specific
antibodies or stained with Imperial protein stain (Thermo Scien-
tific, Somerset, NJ).
Human IgE binding and competition assays
Immulon 4HBX ELISA plates (Thermo Scientific) were coated with
purified CrAra h 1-core (5 lg/mL), Ara h 1 (5 lg/mL), CrAra h 2
(1 lg/mL) or Ara h 2 (1 lg/mL) overnight at 4 °C. Plates were
blocked with PBS containing 0.5% Tween and 1% BSA, washed
ª 2016 The Authors. Plant Biotechnology Journal published by Society for Experimental Biology and The Association of Applied Biologists and John Wiley & Sons Ltd., 14, 1541–1550
Immunotherapy using algal-produced peanut allergens 1547
with PBS-T and then incubated overnight at 4 °C with serum
from peanut-allergic patients diluted in PBS at 1:5 or 1:10 for Ara
h 1 or Ara h 2, respectively. IgE binding was detected with
alkaline phosphatase-conjugated anti-human IgE (Sigma A3525)
and visualized with para-nitrophenyl phosphate (PNPP) at 1 mg/
mL in PNPP substrate buffer (Invitrogen, Carlsbad, CA). Absor-
bances were measured at 405 nm using a Polarstar Omega
spectrophotometer (BMG Labtech, Ortenberg, Germany). For
competition assays, ELISA plates were coated with 5 lg/mL Ara h
1 or Ara h 2 as above. Equal volumes of serum from each patient
were pooled and diluted 1:10. Pooled serum was incubated
overnight at 4 °C with 0, 1, 2, 4 or 8 lg/mL of Ara h 1 or the
molar equivalent of CrAra h 1-core. For Ara h 2, pooled serum
was incubated overnight at 4 °C with 0, 0.625, 1.25, 2.5 or 5 lg/
mL or the molar equivalent of CrAra h 2. Allergen/pooled serum
mixes were added to Ara h 1 or Ara h 2 coated plates in triplicate
and incubated overnight at 4 °C. Plates were washed and IgE
binding was detected as described above.
Mouse peanut sensitization and immunotherapy
All animal procedures were approved by the Institutional Animal
Care and Use Committee of the Icahn School of Medicine at
Mount Sinai under protocol 13-1546. Six-week-old female C3H/
HeJ mice were ordered from the National Cancer Institute.
Sensitization was carried out as previously described (Tordesillas
et al., 2014). The sensitization and immunotherapy schedule is
outlined in Figure 3a and 4a. Briefly, mice were anesthetized,
abdominal fur was removed with depilatory cream, and 500 lg
of peanut extract was applied in PBS and allowed to dry. Purified
native or algal-produced allergens were diluted in PBS and
administered by intraperitoneal injection three times weekly as
follows: 1 lg Ara h 1 (or molar equivalent of CrAra h 1-core)/
injection during week 1–2, 2 lg/injection in week 3, and 5 lg/
injection thereafter.
Basophil activation
Basophil activation was performed as previously described
(Leonard et al., 2012). Briefly, blood was drawn from each
mouse and tested individually or pooled as indicated. Samples
were diluted with RPMI and incubated with purified allergens or
extract at the indicated concentrations for 90 min at 37 °C.
Activation was stopped with PBS containing EDTA. Red blood
cells were lysed using IMMUNO-LYSE (Beckman Coulter, Jersey
City, NJ) as indicated by the manufacturer. Cells were washed
and Fc receptors blocked with anti-CD16/CD32. T and B cells
were gated out with anti-CD3-APC-Cy7 and anti-CD19-APC-Cy7
and basophils were selected using anti-IgE-FITC (clone 23G3) and
anti-CD49b-APC (clone DX5). CD200R-PE (clone ox-110) was
used as a maker for basophil activation. Antibodies were
purchased from eBioscience (San Diego, CA).
Quantification of immunoglobulin titres
Immulon 4HBX ELISA plates were coated with 1 lg/mL purified
native Ara h 1 overnight at 4 °C and blocked with PBS-T with
1% BSA. Pooled serum was tested in triplicate at a 1:100
dilution and each subsequent twofold dilution until 1:12,800.
IgE binding was detected with rat anti-mouse IgE (BD Pharmin-
gen, San Jose, CA; clone R35-72) followed by horse radish
peroxidase (HRP)-conjugated anti-rat IgG. IgG1 binding was
detected with biotin-conjugated anti-mouse IgG1 followed by
streptavidin-conjugated-HRP. Binding was visualized using 1-step
TMB substrate (eBioscience) and absorbances were measured at
450 nm using a Polarstar Omega spectrophotometer (BMG
Labtech).
Allergen challenge and assessment of anaphylaxis
Mice were systemically challenged via intraperitoneal injection
using 10-, 50- and 88-lg doses of purified native Ara h 1 diluted
in PBS (at the prepared concentration, 88 lg was the maximum
dose that could be administered using 200 lL). Body temperature
was measured using a rectal thermometer (WPI Instruments,
Sarasota, FL; model BAT-12) prior to challenge and thirty minutes
after each challenge was administered. A drop in body temper-
ature is indicative of systemic anaphylaxis.
Quantification of mMCP-7
ELISA plates were coated overnight at 4 °C with anti-mouse
tryptase b1/MCPT7 (R&D Systems AF1937) and blocked with PBS-
T with 1% BSA. Serum was diluted in PBS, added to the coated
plate and incubated overnight at 4 °C. Recombinant mMCP-7
(R&D Systems 1937-SE-20) was used as a standard. mMCP-7 was
detected with biotin-conjugated anti-mouse tryptase b1/MCPT7
(R&D Systems, Minneapolis, MN; BAF1937) followed by HRP-
conjugated avidin and visualized using 1-Step TMB substrate.
Absorbances were measured at 450 nm using a Polarstar Omega
spectrophotometer (BMG Labtech).
Statistics
Statistical analyses were calculated using GraphPad Prism soft-
ware. Human IgE binding was compared using a paired t-test.
Statistical significance for allergen challenge was calculated using
one-way ANOVA followed by Bonferroni correction for multiple
comparisons. mMCP-7 levels were compared using a Mann–
Whitney test.
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